View in EDS

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Saved in:
Bibliographic Details
Title: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Authors: Kersting S; Department of Hematology, HAGA Teaching Hospital, The Hague, Netherlands. Electronic address: s.kersting@hagaziekenhuis.nl., Dubois J; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands., Nasserinejad K; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Dobber JA; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Mellink C; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands., van der Kevie-Kersemaekers AF; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands., Evers LM; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., de Boer F; Department of Internal Medicine, Ikazia Hospital, Rotterdam, Netherlands., Koene HR; Department of Hematology, Antonius Hospital, Nieuwegein, Netherlands., Schreurs J; Department of Internal Medicine, Martini Hospital, Groningen, Netherlands., van der Klift M; Department of Internal Medicine, Amphia Hospital, Breda, Netherlands., Velders GA; Department of Internal Medicine, Gelderland Valley Hospital, Ede, Netherlands., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands., van der Straaten HM; Department of Internal Medicine, St Jansdal Hospital, Harderwijk, Netherlands., Hoogendoorn M; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands., van Gelder M; Department of Hematology, MUMC, Maastricht, Netherlands., Posthuma EFM; Department of Internal Medicine, RDGG, Delft, Netherlands., Visser HPJ; Department of Internal Medicine, Northwest Clinics, Alkmaar, Netherlands., Houtenbos I; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, Netherlands., Idink CAM; Department of Internal Medicine, ZorgSaam hospital, Terneuzen, Netherlands., Issa DE; Department of Internal Medicine, Jeroen Bosch hospital, 's-Hertogenbosch, Netherlands., Dompeling EC; Department of Hematology, Isala Hospital, Zwolle, Netherlands., van Zaanen HCT; Department of Internal Medicine, St Franciscus Hospital, Rotterdam, Netherlands., Veelken H; Department of Hematology, LUMC, Leiden, Netherlands., Levenga H; Department of Internal Medicine, Groene Harthospital, Gouda, Netherlands., Tick LW; Department of Internal Medicine, Maxima MC, Eindhoven, Netherlands., Terpstra WE; Department of Internal Medicine, OLVG, Amsterdam, Netherlands., Tonino SH; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands., Boyer M; Roche Products Limited, Welwyn Garden City, UK., Mobasher M; Genentech, South San Francisco, CA, USA., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands., Kater AP; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
Corporate Authors: HOVON CLL study group
Source: The Lancet. Haematology [Lancet Haematol] 2022 Mar; Vol. 9 (3), pp. e190-e199.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35240075
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kersting+S%22">Kersting S</searchLink>; Department of Hematology, HAGA Teaching Hospital, The Hague, Netherlands. Electronic address: s.kersting@hagaziekenhuis.nl.<br /><searchLink fieldCode="AU" term="%22Dubois+J%22">Dubois J</searchLink>; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Nasserinejad+K%22">Nasserinejad K</searchLink>; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Dobber+JA%22">Dobber JA</searchLink>; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Mellink+C%22">Mellink C</searchLink>; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Kevie-Kersemaekers+AF%22">van der Kevie-Kersemaekers AF</searchLink>; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Evers+LM%22">Evers LM</searchLink>; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Boer+F%22">de Boer F</searchLink>; Department of Internal Medicine, Ikazia Hospital, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Koene+HR%22">Koene HR</searchLink>; Department of Hematology, Antonius Hospital, Nieuwegein, Netherlands.<br /><searchLink fieldCode="AU" term="%22Schreurs+J%22">Schreurs J</searchLink>; Department of Internal Medicine, Martini Hospital, Groningen, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Klift+M%22">van der Klift M</searchLink>; Department of Internal Medicine, Amphia Hospital, Breda, Netherlands.<br /><searchLink fieldCode="AU" term="%22Velders+GA%22">Velders GA</searchLink>; Department of Internal Medicine, Gelderland Valley Hospital, Ede, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Spek+E%22">van der Spek E</searchLink>; Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Straaten+HM%22">van der Straaten HM</searchLink>; Department of Internal Medicine, St Jansdal Hospital, Harderwijk, Netherlands.<br /><searchLink fieldCode="AU" term="%22Hoogendoorn+M%22">Hoogendoorn M</searchLink>; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Gelder+M%22">van Gelder M</searchLink>; Department of Hematology, MUMC, Maastricht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Posthuma+EFM%22">Posthuma EFM</searchLink>; Department of Internal Medicine, RDGG, Delft, Netherlands.<br /><searchLink fieldCode="AU" term="%22Visser+HPJ%22">Visser HPJ</searchLink>; Department of Internal Medicine, Northwest Clinics, Alkmaar, Netherlands.<br /><searchLink fieldCode="AU" term="%22Houtenbos+I%22">Houtenbos I</searchLink>; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, Netherlands.<br /><searchLink fieldCode="AU" term="%22Idink+CAM%22">Idink CAM</searchLink>; Department of Internal Medicine, ZorgSaam hospital, Terneuzen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Issa+DE%22">Issa DE</searchLink>; Department of Internal Medicine, Jeroen Bosch hospital, 's-Hertogenbosch, Netherlands.<br /><searchLink fieldCode="AU" term="%22Dompeling+EC%22">Dompeling EC</searchLink>; Department of Hematology, Isala Hospital, Zwolle, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Zaanen+HCT%22">van Zaanen HCT</searchLink>; Department of Internal Medicine, St Franciscus Hospital, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Veelken+H%22">Veelken H</searchLink>; Department of Hematology, LUMC, Leiden, Netherlands.<br /><searchLink fieldCode="AU" term="%22Levenga+H%22">Levenga H</searchLink>; Department of Internal Medicine, Groene Harthospital, Gouda, Netherlands.<br /><searchLink fieldCode="AU" term="%22Tick+LW%22">Tick LW</searchLink>; Department of Internal Medicine, Maxima MC, Eindhoven, Netherlands.<br /><searchLink fieldCode="AU" term="%22Terpstra+WE%22">Terpstra WE</searchLink>; Department of Internal Medicine, OLVG, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Tonino+SH%22">Tonino SH</searchLink>; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Boyer+M%22">Boyer M</searchLink>; Roche Products Limited, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Mobasher+M%22">Mobasher M</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22HOVON+CLL+study+group%22">HOVON CLL study group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2022 Mar; Vol. 9 (3), pp. e190-e199.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35240075
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S2352-3026(22)00034-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e190
    Titles:
      – TitleFull: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kersting S
      – PersonEntity:
          Name:
            NameFull: Dubois J
      – PersonEntity:
          Name:
            NameFull: Nasserinejad K
      – PersonEntity:
          Name:
            NameFull: Dobber JA
      – PersonEntity:
          Name:
            NameFull: Mellink C
      – PersonEntity:
          Name:
            NameFull: van der Kevie-Kersemaekers AF
      – PersonEntity:
          Name:
            NameFull: Evers LM
      – PersonEntity:
          Name:
            NameFull: de Boer F
      – PersonEntity:
          Name:
            NameFull: Koene HR
      – PersonEntity:
          Name:
            NameFull: Schreurs J
      – PersonEntity:
          Name:
            NameFull: van der Klift M
      – PersonEntity:
          Name:
            NameFull: Velders GA
      – PersonEntity:
          Name:
            NameFull: van der Spek E
      – PersonEntity:
          Name:
            NameFull: van der Straaten HM
      – PersonEntity:
          Name:
            NameFull: Hoogendoorn M
      – PersonEntity:
          Name:
            NameFull: van Gelder M
      – PersonEntity:
          Name:
            NameFull: Posthuma EFM
      – PersonEntity:
          Name:
            NameFull: Visser HPJ
      – PersonEntity:
          Name:
            NameFull: Houtenbos I
      – PersonEntity:
          Name:
            NameFull: Idink CAM
      – PersonEntity:
          Name:
            NameFull: Issa DE
      – PersonEntity:
          Name:
            NameFull: Dompeling EC
      – PersonEntity:
          Name:
            NameFull: van Zaanen HCT
      – PersonEntity:
          Name:
            NameFull: Veelken H
      – PersonEntity:
          Name:
            NameFull: Levenga H
      – PersonEntity:
          Name:
            NameFull: Tick LW
      – PersonEntity:
          Name:
            NameFull: Terpstra WE
      – PersonEntity:
          Name:
            NameFull: Tonino SH
      – PersonEntity:
          Name:
            NameFull: Boyer M
      – PersonEntity:
          Name:
            NameFull: Mobasher M
      – PersonEntity:
          Name:
            NameFull: Levin MD
      – PersonEntity:
          Name:
            NameFull: Kater AP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2022 Mar
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3026
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: The Lancet. Haematology
              Type: main
ResultId 1